JP2024527441A - ドープシリコン粒子を含む組成物、及び関連する方法 - Google Patents

ドープシリコン粒子を含む組成物、及び関連する方法 Download PDF

Info

Publication number
JP2024527441A
JP2024527441A JP2024527874A JP2024527874A JP2024527441A JP 2024527441 A JP2024527441 A JP 2024527441A JP 2024527874 A JP2024527874 A JP 2024527874A JP 2024527874 A JP2024527874 A JP 2024527874A JP 2024527441 A JP2024527441 A JP 2024527441A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
particles
doped silicon
composition according
doped
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527441A5 (https=
Inventor
スザンヌ サフィー－シーバート、ロギー
アーメド、ムフタル
ステーラ、フラヴィア
Original Assignee
シサフ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シサフ リミテッド filed Critical シサフ リミテッド
Publication of JP2024527441A publication Critical patent/JP2024527441A/ja
Publication of JP2024527441A5 publication Critical patent/JP2024527441A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024527874A 2021-07-23 2022-07-22 ドープシリコン粒子を含む組成物、及び関連する方法 Pending JP2024527441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2110644.8A GB202110644D0 (en) 2021-07-23 2021-07-23 Improved nucleic acid vector particles
GB2110644.8 2021-07-23
PCT/GB2022/051937 WO2023002222A1 (en) 2021-07-23 2022-07-22 Compositions comprising doped silicon particles, and related methods

Publications (2)

Publication Number Publication Date
JP2024527441A true JP2024527441A (ja) 2024-07-24
JP2024527441A5 JP2024527441A5 (https=) 2025-07-29

Family

ID=77541197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527874A Pending JP2024527441A (ja) 2021-07-23 2022-07-22 ドープシリコン粒子を含む組成物、及び関連する方法

Country Status (7)

Country Link
US (1) US20240327841A1 (https=)
EP (1) EP4351510A1 (https=)
JP (1) JP2024527441A (https=)
CN (1) CN117715612A (https=)
AU (1) AU2022315872A1 (https=)
GB (1) GB202110644D0 (https=)
WO (1) WO2023002222A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202300914D0 (en) 2023-01-20 2023-03-08 Sisaf Ltd Manufacturing process
GB202300915D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd mRNA COMPOSITIONS
GB202300912D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compostions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO2009046220A2 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
IT1394656B1 (it) 2009-07-03 2012-07-05 Brev Angela Srl Processo per la produzione e l'assemblaggio di una siringa per operazioni medicali
GB0913255D0 (en) * 2009-07-30 2009-09-02 Sisaf Ltd Topical composition
NZ606591A (en) * 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2017181115A1 (en) * 2016-04-14 2017-10-19 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
CN112494424A (zh) * 2020-12-04 2021-03-16 合肥澄实生物科技有限公司 一种脂质纳米颗粒制剂及其应用

Also Published As

Publication number Publication date
WO2023002222A1 (en) 2023-01-26
CN117715612A (zh) 2024-03-15
EP4351510A1 (en) 2024-04-17
US20240327841A1 (en) 2024-10-03
GB202110644D0 (en) 2021-09-08
AU2022315872A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
JP7784754B2 (ja) ケイ素ナノ粒子を含む送達システム
US20240327841A1 (en) Compositions comprising doped silicon particles, and related methods
US20240327870A1 (en) Nucleic acid vector compositions
JPH06510036A (ja) 嚢胞性線維症の治療のための組成物および方法
KR20010112301A (ko) 리포좀내에 생활성 복합체의 포집
JP2025525497A (ja) 脂質製剤
KR101916941B1 (ko) 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법
US12594239B2 (en) Protection of biological species from degradation
US20220378905A1 (en) Composite-type nano-vaccine particle
JP2026508828A (ja) 治療用組成物及び治療方法
JP6404034B2 (ja) 核酸を内封してなる中性又はアニオン性リポソーム及びその製造方法。
WO2024153954A1 (en) Therapeutic compositions and methods
WO2022230485A1 (ja) 経肺又は経鼻投与用ワクチン組成物
WO2024153953A1 (en) mRNA COMPOSITIONS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250717